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Tertiary lymphoid tissues (TLTs) are inducible ectopic
lymphoid tissues in chronic inflammatory states and
function as sites of priming local immune responses. We
previously demonstrated that aged but not young mice
exhibited multiple TLTs after acute kidney injury and that
TLTs were also detected in human aged and diseased
kidneys. However, the forms of progression and the
implication for kidney injury remain unclear. To clarify this
we analyzed surgically resected kidneys from aged patients
with or without chronic kidney disease as well as kidneys
resected for pyelonephritis, and classified TLTs into three
distinct developmental stages based on the presence of
follicular dendritic cells and germinal centers. In injury-
induced murine TLT models, the stages advanced with the
extent of kidney injury, and decreased with
dexamethasone accompanied with improvement of renal
function, fibrosis and inflammation. Kidneys from aged
patients with chronic kidney disease consistently exhibited
more frequent and advanced stages of TLTs than those
without chronic kidney disease. Kidneys of patients with
pyelonephritis exhibited more frequent TLTs with more
advanced stages than aged kidneys. Additionally, TLTs in
both cohorts shared similar locations and components,
suggesting that TLT formation may not be a disease-
specific phenomenon but rather a common pathological
process. Thus, our findings provide the insights into
biological features of TLT in the kidney and implicate TLT
stage as a potential marker reflecting local injury and
inflammation.
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T ertiary lymphoid tissues (TLTs) are ectopic lymphoidtissues that are formed under various pathologic con-ditions such as autoimmunity and infection.1–3 TLTs
are composed of a hematopoietic compartment, which
comprises mostly T and B cells, and stromal components, in
particular fibroblasts. The basic functions of TLTs are similar
to those of secondary lymphoid organs such as lymph
nodes.1–3 TLTs have the potential to initiate adaptive immune
responses and produce large amounts of proinflammatory
cytokines. Additionally, some TLTs develop germinal centers,
unique structures in which B cells proliferate rapidly and
undergo class switching, resulting in the generation of
antibody-secreting plasma cells. Besides these functional sim-
ilarities, TLTs and secondary lymphoid organs also rely on
related molecules for their development, including the ho-
meostatic CXC chemokine ligand 13 (CXCL13) and retinoic
acid.1–5
The role of TLT in the host organ is context-dependent
and can be beneficial or detrimental.1–3 In patients with
rheumatoid arthritis, for instance, multiple TLTs develop in
the synovium and generate pathogenic autoantibodies such as
anti-cyclic citrullinated protein/ peptide antibodies, which
are used as a specific, diagnostic, and prognostic marker of
rheumatoid arthritis.6–9 In contrast, during infections, TLTs
are induced as an integral part of anti-pathogen immunity at
local site, though a failure to eradicate a pathogen can lead to
the development of autoimmunity. In a previous study, we
found that aged but not young mice developed multiple renal
TLTs after acute kidney injury.10 TLTs occupied a broad area
of renal parenchyma and promoted inflammation. The TLT
size was closely associated with impaired renal function and
increased expression of proinflammatory cytokines such as
tumor necrosis factor-a and interferon-g.10 Additionally,
depletion of CD4-positive cells as well as dexamethasone
treatment prevented TLT formation and improved renal
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outcomes.10 Although these interventions did not specifically
target TLTs, we speculated that age-dependent formation of
TLTs in the diseased kidneys was detrimental for the host.10,11
TLTs were also detected in aged human kidneys, with a
composition similar to those of mouse TLTs.10 In addition
to aged human kidneys, TLTs were observed in kidneys of
patients with autoimmune diseases,12 renal allograft rejec-
tion,13,14 and in IgA nephropathy.15 However, the compre-
hensive understanding of TLTs in human kidney is still
lacking,16 and little information is available on their precise
incidence, causes, variation in different etiologies, and clinical
relevance. One of the reasons for this may be that most of the
prior investigations of renal TLT relied on a small number of
patients or TLTs from limited kidney tissue obtained via
needle biopsy, which might not be sufficient to representa-
tively reflect renal TLTs. In addition, though renal biopsy
remains an important tool in the management of kidney
diseases and provides prognostic information independent of
clinical predictors such as proteinuria,17 the indication of
renal biopsy is limited to certain chronic kidney disease
(CKD) populations because of the risk for complications such
as bleeding. Another reason is that the phenotypic hetero-
geneity of TLTs complicated our understanding of the clinical
relevance of TLTs in human kidneys. TLTs develop postnatally
through a multistep process that might contribute to their
heterogeneity.1–3 The accurate and reliable recognition of
TLTs and their developmental stages seems a prerequisite for
better understanding of TLTs in human kidneys. To date,
however, the extent of TLT heterogeneity has not been
explored, especially in human kidneys, and the relationship
between the heterogeneity and disease severity also remains
unclear.
In this study, we analyzed surgically resected human kid-
ney samples from patients with pyelonephritis, because
infection is a strong trigger of TLT development in various
tissues1–3 and found multiple TLTs developed in human py-
elonephritis kidneys. Combined with the data from aged
patients and the aged murine model we have established,10 we
provide evidence that TLT formation is a common pathogenic
process that proceeds through several distinct developmental
stages irrespective of etiology. Furthermore, we established a
phenotypic evaluation method for TLTs in human kidneys
based on the presumed developmental stages and showed that
the TLT stages were associated with the severity of kidney
injury in mice and humans and could be reversible even after
TLTs mature into advanced stages.
RESULTS
Human pyelonephritis kidneys show multiple lymphocyte
aggregates
Infection is a strong trigger of TLT development in various
tissues,1–3 but whether TLTs form in human pyelonephritic
kidneys has not been investigated. To investigate this, we
examined sections of kidneys surgically removed because of
pyelonephritis. The clinical features of these patients are listed
in Table 1. We confirmed that kidneys of the patients with
pyelonephritis exhibited diffuse interstitial scarring and
tubular atrophy with thyroidization and in some cases acute
pyelonephritis with infiltrates of neutrophils (Supplementary
Figure S1A–C), all of which are typical histologic findings in
pyelonephritic kidneys.18,19 Pyelonephritic kidneys exhibited
multiple mononuclear cell aggregates with a unique distri-
bution (Figure 1). A chain of aggregates appeared just under
the renal capsule and near the corticomedullary junction
(Figure 1a; Supplementary Figure S2A), preferentially in close
proximity to blood and lymphatic vessels (Figure 1c;
Supplementary Figure S3). Additionally, aggregates were
found along glomeruli (Figure 1d), developing in the peri-
renal tissue, hilus, and submucosa of the renal pelvis
(Supplementary Figure S2B–D). This localization of aggregates
in pyelonephritic kidneys was similar to that of aged kidneys
(Supplementary Figure S4). Almost no aggregates were
detectable in mildly injured areas (Supplementary Figure S5A).
In contrast, in more severely injured regions, larger aggregates
were noted (Supplementary Figure S5B and C). There were
no inflammatory cellular aggregates in the medulla, although
tissue destruction was detected broadly (Supplementary
Figure S5D). These aggregates were composed mainly of T
and B lymphocytes (Figure 1b, e, and f).
Cellular and molecular components of TLTs in pyelonephritis
are similar to those of age-dependent TLTs
In the present study, we defined TLTs as the organized
lymphocyte aggregates with signs of proliferation. Immuno-
histochemical analysis revealed major intra- and interpatient
heterogeneity in TLT phenotypes (the list of markers related
with TLTs in human kidneys is presented in Supplementary
Table S1). TLTs with no distinct T- and B-cell area
(Figure 2a and b) but with a-smooth muscle actin (a-SMA)–
positive fibroblastic network (Figure 2c) were observed in
regions with relatively mild injury. In contrast, TLTs in highly
destroyed areas harbored organized B-cell follicles, sur-
rounded by T cells (Figure 2d). CD21-positive follicular
dendritic cell (FDC), a dendritic-shape stromal cell in charge
of organizing B-cell homeostasis and humoral immune re-
sponses in secondary lymphoid organs,20 formed B-cell
Table 1 | Clinical characteristics of German patients with













A diagnosis of pyelonephritis was based both on clinical and histologic findings
compatible with pyelonephritis.
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follicles (Figure 2d and e). Additionally, some of the aggre-
gates with an FDC network developed B-lymphocyte clusters
with pronounced proliferative activity (Figure 2f), indicating
the formation of germinal centers. Plasma cells were also
detectable around TLTs (Figure 2g), suggesting the occurrence
of B-cell maturation in TLTs. Homeostatic chemokine
CXCL13-positive cells including FDCs were detected within
aggregates, and they were negative for CD45 (Figure 2h and
i). FDCs were positive for p75 neurotrophin receptor, a neural
crest marker (Figure 2k), and were surrounded by fibroblast-
like cells positive for retinaldehyde dehydrogenases 2, a rate-
limiting enzyme in retinoic acid synthesis (Figure 2j), as we
previously reported in aged human kidneys.10 T cells within
TLTs were mainly CD4-positive (Figure 2l and m), some of
which were positive for Foxp321,22, a master regulator of
regulatory T cells21 (Supplemental Figure S6). Macrophages
were detectable around TLTs, but they were sparse inside
TLTs (Figure 2n and o). These cellular and molecular com-
ponents of TLTs in pyelonephritic kidneys showed marked
similarity to those in age-dependent TLTs.10 We also found
that some of the CD21-positive FDC networks were
composed of 2 subdomains (Supplementary Figure S7A
and B): the proliferating B-cell cluster area with CD21 weakly
positive FDC area and the scattered proliferating B-cell area
with CD21 strongly positive FDC area. This is reminiscent of
the dark zone and light zone of germinal center in secondary
Figure 1 | Human pyelonephritic kidneys exhibited multiple lymphocyte aggregates. Histological analysis of human pyelonephritic
kidneys. (a,c,d) Periodic acid–Schiff staining showed a chain of aggregates extending over long areas (a) just under the renal capsule and (c)
multiple aggregates around blood vessels and (d) in periglomerular areas. (b,e,f) Immunofluorescence of CD3ε (a T-cell marker) and
CD20 (a B-cell marker) in areas (b) just under the renal capsule, (e) around blood vessels, and (f) in glomeruli. Yellow and white boxes indicate
the localization of aggregates. The white dotted line in part (b) indicates the renal capsule, whereas the dotted line in part (e) indicates
the location of an artery. Bars ¼ (a) 300 mm, (b,d) 100 mm, (c) 200 mm, and (e,f) 50 mm. To optimize viewing of this image, please see the online
version of this article at www.kidney-international.org.
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lymphoid organs, which correspond to the sites of B-cell
proliferation and hypermutation, and of antigen-driven se-
lection, respectively.23
TLT classification into 3 stages based on the presence of FDCs
and germinal centers
Phenotypic analysis of TLTs revealed that TLTs could be
classified into distinct phenotypes, based on the presence of
CD21-positive FDCs, and germinal centers, in other words,
dense Ki67-positive B-cell clusters, within TLTs (Figure 3a–c).
TLTs containing neither FDCs nor germinal centers were
defined as stage I TLTs, whereas TLTs that contain FDCs but
lack germinal centers were defined as stage II TLTs. TLTs with
prominent FDCs and germinal centers were defined as stage
III. Stage I TLTs were composed of mixed T- and B-cell ag-
gregates, while stage II or III TLTs were composed of B-cell
clusters, surrounded by T cells (Figure 3b). Whereas scattered
Ki67-positive cells were detected in FDC network areas in
stage II TLTs, Ki67-positive cell clusters, in other words,
germinal centers, were detected in those with stage III TLTs
(Figure 3a).
In stage III TLT, we found a unique subpopulation of fi-
broblasts just around FDCs, which was negative for a-SMA
and CD21 (Figure 3d) but positive for CXCL13 (Figure 3e).
This unique localization and intermediate phenotype sug-
gested the existence of fibroblasts with a transitional property
between myofibroblasts and FDCs, which were reminiscence
of pre-FDCs in the spleen.24
TLTs and lymphocyte infiltration are distinguishable in their
cellular composition and functional potential for lymphocyte
activation
Although TLTs in advanced stages, which contain FDCs, are
easily distinguishable from lymphocyte infiltration, the
identification of early stage TLTs requires more accurate
characterization. Immunostaining of CD3ε and B220 of aged
injured kidneys showed that T lymphocytes were observed
broadly in renal parenchyma (Figure 4a and b), whereas B
lymphocytes were almost exclusively present within and just
around TLTs (Figure 4a and b), consistent with the observa-
tion in TLTs in tumor microenvironment25 and chronically
rejected transplanted organs.13 Quantitative analysis of the
number of T and B cells in the interstitium with or without
stage I TLTs in aged injured kidney revealed that B cell–T cell
ratios were remarkably higher in stage I TLTs compared with
those in lymphocyte infiltration (Figure 4c). Because B cells
are recruited mainly by CXCL13, a powerful driving force for
B-cell recruitment,4 we stained CXCL13 and confirmed that
CXCL13 was exclusively expressed within TLTs and were
detected in most of the stage I TLTs in aged injured kidneys
(Figure 4d and e), which is consistent with our previous
study.10 These results suggest that the difference in B cell–T
cell ratios between stage I TLTs and lymphocyte infiltration
could be derived from the exclusive expression of CXCL13
within TLTs. In addition, we also confirmed that stage I TLTs
contained many proliferating lymphocytes (Figure 4f and g).
We also analyzed stage I TLTs and lymphocyte infiltration in
human kidneys and confirmed higher B cell–T cell ratios,
presence of proliferating lymphocytes, and CXCL13 expres-
sion in stage I TLTs (Figure 4h–n), although, unlike mouse
stage I TLTs, stage I TLTs containing CXCL13 signals were not
so frequent in human kidneys. Taken together, stage I TLTs
and lymphocyte infiltration are clearly distinguishable by
their cellular composition and functional potential for
lymphocyte activation. A B-cell cluster is a defining charac-
teristic of TLTs and is sufficient for identifying TLTs.
TLT stages reflect the severity of kidney injury in murine
kidneys
To better understand the relation between TLT stage and renal
damages, we used our murine model inducing renal TLTs. In
our previous study, we showed that 12-month-old mice
exhibited multiple TLTs after ischemic reperfusion injury
(IRI) in an ischemia time-dependent manner.10 TLTs
expanded and occupied larger areas of renal parenchyma as
the time after IRI increased.
We now defined and classified mouse TLTs based on our
staging of human TLTs (Figure 5a). In parallel to the
expansion of TLTs, the numbers of total TLTs consistently
increased over time after IRI (Figure 5b; Supplementary
Table S2A) and the number and proportion of advanced-
stage TLTs (stage II and III TLTs) consistently increased over
time after IRI (Figure 5c–e; Supplementary Table S2B and C),
indicating that TLT stage reflects developmental stage of TLTs.
The total TLT numbers, advanced-stage TLT numbers, and
the proportion of advanced-stage TLTs were also higher in
kidneys with 45-minute IRI than in those with 30-minute IRI
(Figure 5f–i; Supplementary Table S2D–F), suggesting the
potential of TLT stage as a marker for kidney injury and
inflammation. In our previous study, we showed that 23-
month-old mice develop TLT spontaneously without
injury.10 Here we noted that total TLT numbers as well as the
numbers of advanced TLTs in 23-month-old mice were
smaller than those in IRI-induced models (Figure 5f–h;
=
Figure 2 | Cellular and molecular components of tertiary lymphoid tissue in pyelonephritic kidneys. Immunohistochemical analysis
of human pyelonephritic kidneys. Immunofluorescence of (a) CD3ε (a T-cell marker) and CD20 (a B-cell marker); (b) Ki67; (c) CD21 (a follicular
dendritic cell marker), a-smooth muscle actin (a-SMA), and 40,6-diamidino-2-phenylindole (DAPI); (d) CD3ε and CD20; (e) CD21, a-SMA,
and CD45; (f) Ki67; (h) CXC chemokine ligand 13 ([CXCL13], a homeostatic chemokine) and CD21; (i) CXCL13 and CD45; (k) p75 neurotrophin
receptor ([p75NTR], a neural crest marker) and CD21; (l) CD4; (m) CD8; (n) CD3ε and CD20; and (o) CD163 (a macrophage marker) and
Ki67. (g) Periodic acid–Schiff (PAS) staining of plasma cells. (j) Immunohistochemical analysis of retinalaldehyde dehydrogenase 2 (RALDH2).
Parts (a–c), (d–f), (l,m), and (n,o) are serial sections. (j) The yellow dotted line indicates the border of B-cell follicles. Bars ¼ (d–f,k–m)
100 mm, (a–c,j,n–o) 50 mm, and (g–i) 10 mm. To optimize viewing of this image, please see the online version of this article at www.kidney-
international.org.
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Figure 4 | Stage I tertiary lymphoid tissues (TLTs) were distinct from lymphocyte infiltration. Immunofluorescence of stage I TLTs and
lymphocyte infiltration in murine and human kidneys. (a–g) Analysis of stage I TLTs and lymphocyte infiltration in aged injured kidneys
in mice. Immunofluorescence of (a,b) CD3ε (a T-cell marker) and B220 (a B-cell marker); (d,e) CXC chemokine ligand 13 ([CXCL13], a
homeostatic chemokine), CD45, and 40,6-diamidino-2-phenylindole (DAPI) in lymphocyte infiltration and stage I TLTs 8 and 24 days after 45-
minute ischemic reperfusion injury in 12-month-old mice. (f,g) Immunofluorescence of (f) CD3ε, Ki67, and DAPI, and (g) B220, Ki67, and DAPI in
stage I TLTs. (c) B cell–T cell ratio in stage I TLTs (TLT) and lymphocyte infiltration (non-TLT) (n ¼ 7 per group), calculated by dividing the
numbers of B cells by the numbers of T cells in each area. (h–n) Analysis of stage I TLTs and lymphocyte infiltration in aged and pyelonephritis
human kidneys. Immunofluorescence of (h,i) CD3ε and CD20; (k,l) CXCL13 and CD45 in stage I TLTs and lymphocyte infiltration. (m,n)
Immunofluorescence of (m) CD3ε, Ki67, and DAPI, and (n) CD20, Ki67, and DAPI in stage I TLTs. (j) B cell–T cell ratio in stage I TLTs (TLT) and
lymphocyte infiltration (non-TLT) (n ¼ 7 per group) in human kidneys. (b,i) The white arrows indicate the localization of TLTs, and the white
arrowheads are (f,m) proliferating T cells and (g,n) proliferating B cells. The white dotted lines indicate the border of (e–g) stage I TLTs and (i,l)
renal capsules. (c,j) Values are means  SD. (c,j) A 2-tailed Student’s t test was used to analyze data. *P < 0.01. Bars ¼ (a,b) 50 mm, (d–g,k–n) 10
mm, and (h,i) 100 mm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
=
Figure 3 | Tertiary lymphoid tissues were classified into 3 stages based on the presence of follicular dendritic cells and germinal
centers. Representative immunofluorescence micrographs of 3 distinct stages (I, II, III) of tertiary lymphoid tissues in human kidneys.
Immunofluorescence of (a) CD21 (a follicular dendritic cell marker), Ki67 (a cell proliferation marker), and 40,6-diamidino-2-phenylindole
(DAPI); (b) CD3ε (a T-cell marker) and CD20 (a B-cell marker); and (c) CD21, a-smooth muscle actin (a-SMA), and DAPI. (b,c) Each stage is a
serial section. Immunofluorescence of (d) CD21 and a-SMA and (e) CXC chemokine ligand 13 (CXCL13) and CD21 (serial sections). (d,e) The
white dotted lines indicate the border of the CD21/a-SMA–double negative zone. Bars ¼ 50 mm. To optimize viewing of this image, please see
the online version of this article at www.kidney-international.org.
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Figure 5 | The developmental stage of tertiary lymphoid tissues (TLTs) was associated with the severity of kidney injury in mice.
(a) Histologic analysis of aged injured kidneys in mice. Immunofluorescence of CD21 and Ki67 shows 3 types of TLTs in aged injured
kidneys. White arrows indicate the localization of the germinal center. (b–g) Quantification of the TLT numbers and stages in aged mouse
kidneys. Number of (b) total TLTs; (c) stage I, II, and III TLTs; and (d) advanced-stage TLTs; as well as (e) the proportion of stage I, II, and III
TLTs at various time points after 45-minute ischemic reperfusion injury (IRI) in 12-month-old mice (days 0 and 8: n ¼ 6, day 24: n ¼ 5, day 35:
n ¼ 6, day 45: n ¼ 7). (d) The numbers of advanced-stage TLTs (stage II and III TLT) significantly increased over time after IRI (P < 0.01)
(Supplementary Table S2B). The number of (f) total TLTs; (g) stage I, II, and III TLTs; and (h) advanced-stage TLTs; as well as (i) the proportions
of stage I, II, and III TLTs in 23-month-old mouse kidneys without injury (n¼ 12), and 12-month-oldmouse kidneys 45 days after 30-minute (n¼ 7)
or 45-minute (n ¼ 7) IRI. (h) The numbers of advanced-stage TLTs in 45-minute IRI were significantly higher than those of 30-minute IRI and
23-month-oldmouse kidneys (P< 0.01) (Supplementary Table S2E). (b–d,f–h) Values aremeans SD. Data were analyzed using (b,d) (continued)
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Supplementary Table S2D) and 88% of these TLTs in 23-
month-old mice were in stage I (Figure 5i). The difference
in total TLT numbers and advanced-stage TLT numbers
between 23-month-old mouse kidneys and 45-minute IRI
kidneys was 0.80 per mm2 (95% confidential interval [CI],
0.66–0.93) and 0.72 per mm2 (95% CI, 0.61–0.84), respec-
tively (Supplementary Table S2D and E).
TLT stages are reversible in murine kidneys
To investigate whether TLT stages can regress, we adminis-
tered dexamethasone (Dex) from 35 days after an ischemic
insult (Figure 6a), when TLTs at stage I and II are already
established (Figure 5c–e). Ten days later, the kidneys of Dex-
treated mice exhibited significantly smaller TLTs (Figure 6b
and c) at less advanced stages (Figure 6e-g; Supplementary
Table S3B and C) than those at day 35, although the total
numbers of TLTs were not statistically different among day 35,
day 45, and day 45 treated with Dex (Figure 6d;
Supplementary Table S3A). Consistent with this, the expres-
sion of homeostatic chemokines, proinflammatory cytokines,
and fibrosis markers was also significantly reduced in Dex-
treated mice (Figure 6h), and the expression of these
markers strongly correlated with TLT sizes (Figure 6i). The
number of Foxp3-positive T cells and the expression levels of
Foxp3 were also reduced in Dex-treated mice (Supplementary
Figure S8A and B).
Dex treatment suppressed TLT formation and improved renal
function with fibrosis resolution in murine adenine
nephropathy
To investigate whether TLT resolutions are accompanied with
the improvement in renal function, we induced adenine ne-
phropathy model in aged wild-type mice and administered
either Dex or vehicle from 12 days after the initiation of
adenine diet feeding (Figure 7a). Twenty-one days after dis-
ease induction and 9 days of treatment, aged vehicle-treated
mice exhibited several advanced TLTs and renal dysfunction
(Figure 7b–h). Treatment with Dex fully abolished the for-
mation of TLTs and led to significantly improved renal
function compared with that of vehicle-treated mice
(Figure 7b–h). Consistent with this, the expressions of ho-
meostatic chemokines Cxcl13 and Ccl19 and proinflammatory
cytokines were significantly reduced in Dex-treated mice
(Figure 7i). Renal fibrosis score, which was quantified as a-
SMA-positive area in the renal interstitial space, and the
expression of fibrosis markers such as Col1a1 and Fn1 were
also improved in Dex-treated mice (Figure 7j–l).
TLT stages in aged and pyelonephritic human kidneys
Finally, we examined the developmental stages of renal TLTs
in aged patients and patients with chronic pyelonephritis (n ¼
69 and n ¼ 16, respectively). In this study, CKD were defined
as either estimated glomerular filtration rate (eGFR) < 60 ml/
min per 1.73 m2 or positive urinary protein. The clinical
characteristics evaluated in this study are summarized in
Tables 1 and 2. Whereas 47.8% of aged patients exhibited
TLTs, all patients with pyelonephritis exhibited TLTs
(Figure 8a). Among patients with TLTs, patients with pyelo-
nephritis, compared with aged patients, exhibited significantly
higher numbers of total TLTs and advanced-stage TLTs and a
higher proportion of advanced-stage TLTs (Figure 8b–e;
Supplementary Table S4A–C). The difference in total TLT
numbers between aged kidneys and pyelonephritic kidneys
was 0.22 per mm2 (95% CI, 0.16–0.28) (Supplementary
Table S4A). To compare renal TLTs related to aging alone
and those driven by kidney injury, we further classified the
aged patients into 2 groups: aged patients with or without
CKD (n ¼ 29 and n ¼ 40, respectively). TLTs were detectable
in the kidneys of 43% of patients without CKD and 55% of
those with CKD (Figure 8f). Consistent with the results in
mice, almost 90% of renal TLTs in aged patients without CKD
were stage I TLTs. Among aged patients with TLTs, patients
with CKD, compared with patients without CKD, exhibited
significantly higher numbers of total TLTs and advanced-stage
TLTs and a hhigher proportion of advanced-stage TLTs
(Figure 8g–j and Supplementary Table S4D–F). Among aged
patients with renal TLTs, the numbers of total and advanced-
stage TLTs as well as the proportion of advanced-stage TLTs
were not statistically different between aged patients in the
presence or absence of proteinuria or a reduced GFR
(eGFR < 60 ml/min per 1.73 m2) (Supplementary Figure S9).
DISCUSSION
In the present study, we analyzed surgically resected human
pyelonephritis kidneys and found multiple heterogeneous
TLTs, which gave us a unique opportunity to comprehensively
understand TLTs in human kidneys. To our knowledge, this is
the first study to demonstrate an association between the
developmental stage of TLT and kidney injury in mice and
humans from 2 independent cohorts, supporting the poten-
tial of TLT stage as a marker reflecting local injury and
inflammation. Additionally, we showed that TLT stages
decreased with Dex treatment accompanied with improve-
ment of renal inflammation, indicating the reversibility of
TLT stages. Furthermore, we have shown that the adminis-
tration of Dex suppressed TLT formation and improved renal
function and fibrosis. Moreover, we found spatial and
developmental similarities of TLTs in patients with pyelone-
phritis and aged patients, indicating that TLT formation may
not be disease-specific but rather a common pathological
process. Although TLT development in human kidneys has
been observed in several disease conditions,10,12,13,15,26,27 the
number of diseases in which renal TLTs can be observed is
=
Figure 5 | (continued) a trend test, (e,i) a generalized estimating equation, and (f,h) 1-way analysis of variance with Bonferroni post hoc
analysis. The numbers of TLTs are the numbers per unit area of cortex (per mm2). *P < 0.01. Bars ¼ 50 mm. To optimize viewing of this image,
please see the online version of this article at www.kidney-international.org.
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predicted to increase further. Taken together, these findings
provide insight into the biological features of TLTs in the
kidney and implicate TLT stage as a potential inflammatory
marker.
TLT is a specialized microenvironment for lymphocyte
activation (Figure 9), which clearly distinguishes TLTs from
simple inflammatory cell infiltration,1–3 even in the early stage
(stage I TLT). TLTs are characterized by distinct phenotypic
fibroblasts within TLT, which produce homeostatic chemo-
kines such as CXCL13.10,11,28 Consistently, the T cell–B cell
ratio clearly distinguished stage I TLTs from lymphocyte
infiltration (Figure 4a–c and h–j). Indeed, it has been previ-
ously demonstrated that, whereas infiltrating T cells are
broadly detectable across the organs, infiltrating B cells are
almost exclusively detectable in the form of TLTs in tumor
microenvironment,25 as well as in chronically rejected trans-
planted kidneys.13
A sustained overproduction of proinflammatory cytokines
by lymphocytes activated in TLTs has been implicated as a
primary reason why inflammation fails to resolve in various
tissues.1–3,29 In addition, autoantibody production in TLTs
has been demonstrated to contribute to local pathology.30
Finally, unlike lymph nodes, TLTs are not encapsulated, and
thus can markedly expand in the renal interstitial compart-
ment and occupy broad areas of the renal parenchyma. These
considerations and findings suggest that TLTs play important
roles in persistent inflammation and tissue destruction that
characterize kidney disease progression. Alternatively, TLTs
also can play immunoregulatory roles.31 In the murine
atherosclerosis model, for instance, TLTs convert naïve T cells
into induced Foxp3-positive regulatory T cells and control
chronic inflammation.32 In this study, Foxp3-positive regu-
latory T cells were detectable within TLTs (Supplementary
Figures S6 and S8), though the numbers were not relatively
large, and decreased after Dex treatment (Supplementary
Figure S8). Therefore, TLTs can enforce or attenuate
chronic inflammation and the balance is context-dependent.
The frequency and developmental stage of TLTs might be
distinct for each underlying kidney disease. In this study, we
showed that the incidence of TLTs was 100% in patients with
chronic pyelonephritis, whereas only about 50% of aged pa-
tients developed TLTs. Additionally, we found a large differ-
ence in total and advanced-stage TLT numbers between aged
kidneys and pyelonephritic kidneys. In TLTs driven by
infections, such as inducible bronchus-associated lymphoid
tissue, the occurrence, size, and number depend on the type
and duration of antigenic exposure.33,34 In the present study,
all patients with pyelonephritis had severe disease refractory
to medications and had to undergo nephrectomy, indicating
long-time antigen exposure that explains the high frequency
and advanced stages of TLTs in these patients.
The frequency of TLTs in aged kidneys in this study
(around 50%) was higher than that in our previous report
(28%).10 This difference likely results from different defini-
tions of TLTs. In our previous study, we defined TLTs as in-
flammatory cell aggregates containing CXCL13- and Ki67-
positive cells,10 while in this study we defined TLTs as orga-
nized lymphocyte aggregates with signs of proliferation. Most
studies have defined TLTs as organized lymphocyte aggre-
gates. Additionally, CXCL13 is not constitutively detectable by
immunostaining due to the limitation of sensitivity even in
FDCs in secondary lymphoid organs,35 which may lead to an
underestimation of the TLT frequency in our previous study.
Our finding that TLTs occur in up to 50% of aged patients is
also of interest given that, Furman et al.36 have recently re-
ported that the elderly patients can be stratified based on the
expression of inflammasome genes, into an inflammatory and
noninflammatory aged patient group. It remains to be proven
whether an inflammatory background of the host may indeed
predispose to TLT formation in human aged kidneys.
An important component in this study was to use a mu-
rine model of renal TLTs to assess the temporal relationship
between TLT development and tissue damage. We demon-
strated that the severity of kidney injury determined by
ischemia time affected TLT development. These findings were
also supported by experimental evidence showing that the
induction of TLTs was dependent, at least partly, on the
expression levels of inflammatory cytokines such as tumor
necrosis factor-a and lymphotoxin.13,24 We therefore specu-
late that the heterogeneity of TLTs in human kidneys, as
described, may relate to the variable severity of injury.
Interestingly, most of the age-dependent spontaneous TLTs in
mice are stage I TLTs, suggesting that aging alone is not suf-
ficient, and massive cell death is required for driving more
advanced-stage TLTs. Additionally, we showed that even
advanced-stage TLTs can respond to Dex treatment, shrink,
and revert to less advanced stages in the murine model. This
result indicates that therapeutic approaches to reverse TLT
=
Figure 6 | The developmental stages of tertiary lymphoid tissues (TLTs) were reversible with the treatment of dexamethasone (Dex)
in mice. Quantification of TLT numbers and stages of 12-month-old mouse kidneys at 45 days after 45-minute ischemic reperfusion injury (IRI)
treated with Dex from day 35 (45 Dex) (n ¼ 9). (a) Experimental protocol; (b) periodic acid–Schiff staining; (c) cumulative TLT sizes per
cortex; (d) total TLT numbers; (e) stage I, II, and III TLT numbers; (f) advanced TLT numbers; and (g) the proportion of stage I, II, and III TLTs in
12-month-old mouse kidneys 35 and 45 days after 45-minute IRI (day 35: n ¼ 6, day 45: n ¼ 7 per group), and 12-month-old mouse kidneys
45 days after 45-minute IRI treated with Dex from day 35 (45 Dex) (n ¼ 9). (h) Cxcl13, Ccl19 (a homeostatic chemokine), Tnfa, Ifng, Col1a1,
and Fn1 mRNA levels in the IRI kidneys, and (i) their associations with TLT sizes (35: aged kidneys 35 days after 45-minute IRI; 45: aged
kidneys 45 days after 45-minute IRI; 45 Dex: aged kidneys treated with Dex from days 35–45). (b) Yellow dash lines indicate the localization of
TLT. (c) The TLT sizes were expressed relative to those of aged IRI kidneys 35 days after 45-minute IRI. The expression levels of mRNA were
normalized to those of Gapdh and expressed relative to those of aged IRI kidneys 35 days after IRI. Reverse transcriptase polymerase chain
reaction primer sequences are listed in Supplementary Table S5. (c–f,h) Values are means  SD. Data were analyzed using (c,d,f–h) 1-way
analysis of variance with Bonferroni post hoc analysis and (g) a generalized estimating equation. The number of TLTs was shown as
the numbers per unit area of cortex (per mm2). *P < 0.01; **P < 0.05. (i) Correlation was determined by Pearson’s correlation analysis.
Bars ¼ 300 mm. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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stages could be promising to attenuate intrarenal aberrant
inflammation. Given that renal biopsy is an invasive pro-
cedure and might not be sufficient to representatively reflect
renal TLTs, biomarkers reflecting TLT stages should ideally be
invented. Further molecular insights into the TLT stages are
required to yield specific biomarkers reflecting TLT
development.
We found a unique subpopulation of fibroblasts around the
FDC-harboring germinal center (Figures 3 and 9). These fi-
broblasts were characterized by their specific localization and
Figure 7 | Dexamethasone (Dex) treatment abolished tertiary lymphoid tissue (TLT) formation and improved renal function as well as
fibrosis in murine adenine nephropathy model. (a) Experimental protocol for parts (b–l) (n ¼ 3–4 in each group). Dex treatment
abolished TLT formation and improved renal function as well as renal fibrosis in 10-month-old female mice subjected to 0.25% adenine
nephropathy models as shown by (b) serum creatinine (Cr) levels; (c) total TLT numbers; (d) advanced-stage TLT numbers; (e) periodic acid–
Schiff staining; (f) immunofluorescence of CD3ε (a T-cell marker) and CD20; (g) stage I, II, and III TLT numbers; (h) the proportion of stage I, II,
and III TLTs among all TLTs; (i) Cxcl13, Ccl19 (a homeostatic chemokine), Tnfa, and Ifng mRNA levels; (j) immunofluorescence of a-smooth
muscle actin (a-SMA); (k) fibrosis area; and (l) Col1a1 and Fn1 mRNA levels. (b–d,g,i,k–l) Values are means  SD. (e) Yellow dash lines indicate
the localization of TLT. Bars ¼ 50 mm. (i,l) The expression levels of mRNA were normalized to those of Gapdh and expressed relative to those
of Dex-treated kidneys. The numbers of TLTs are the numbers per unit area of cortex (per mm2). Reverse transcriptase polymerase chain
reaction primer sequences are listed in Supplementary Table S5. (b–d,i,k,l) Data were analyzed using 2-tailed Student’s t test. *P < 0.01. PBS,
phosphate-buffered saline. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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intermediate phenotype between myofibroblasts and FDCs.
Similar stromal cells have been detected in the spleen and are
called pre-FDC because they are interconnected with FDC and
possess some FDC-like phenotypes such as the ability to pro-
duce CXCL13, but they lack CD21 expression.24 The fibroblast
subpopulation identified in this study met the above-
mentioned definition of pre-FDC (Figure 9). Further study is
required to determine their function and relevance in TLT
formation.
An interesting observation in our study was that TLT
developed around perivascular and subcapsular areas in hu-
man kidneys irrespective of the etiology. This is consistent
with our previous finding that TLTs formed around the per-
ivascular area in murine kidney10 and a previous report24
showing that FDCs in the spleen developed from peri-
vascular precursors were positive for platelet-derived growth
factor receptor-b and were of stromal cell origin. These lo-
cations are the areas rich in lymphatic vessels, and further
study is needed to determine the mechanism by which TLT
develops exclusively in these specific areas.
This study has several limitations. First, our results pro-
vided snapshots of different phenotypic TLTs in human kid-
neys. However, in support of our hypothesis, we confirmed a
multistep TLT development in parallel to phenotypic
diversification of resident fibroblasts in mice (Figure 5a).
Second, there was a possibility of underestimation of TLT
stages with the use of only 2 serial sections. Nevertheless, we
obtained consistent results in the relation between TLT stage
and kidney injury from murine models and 2 independent
human cohorts. Analysis of a large number of TLTs may
compensate for errors in TLT staging. Finally, although the
nephrectomy samples due to renal cell carcinoma (RCC) that
were examined in this study were free of cancer, the possi-
bility that the cancer environment contributed to the devel-
opment of TLTs cannot be completely excluded.
In summary, we found the heterogeneity of TLTs in the
kidney and demonstrated an association between the devel-
opmental stages of TLTs and the severity of kidney injury. Our
data also might shed new light on TLT biology in the kidney
and provide a further rationale for studying TLT formation as
a potential inflammatory marker as well as therapeutic target
in various kidney diseases.
METHODS
For detailed methods, please see the Supplementary Methods.
Analysis of human kidney specimens
All human specimens were procured and analyzed after informed
consent and with approval of the ethics committee at Kyoto Uni-
versity Hospital and Rhenish-Westphalian Technical University of
Aachen Hospitals. Kidneys from aged patients with RCC who un-
derwent nephrectomy at Kyoto University Hospital (Kyoto, Japan)
and from patients with chronic pyelonephritis who underwent ne-
phrectomy at Rhenish-Westphalian Technical University of Aachen
Hospitals (Aachen, German) were analyzed. We defined aged pa-
tients as those 60 years and older. Experienced pathologists
confirmed that all of the RCC nephrectomy samples analyzed in this
study were free of carcinoma. Because TLTs can develop as a result of
certain diseases, patients who had a clinical history or laboratory
evidence or both of the following diseases were excluded from the
analysis of the aged kidney samples from Kyoto University Hospitals:
(i) pyelonephritis; (ii) glomerulonephritis; (iii) autoimmune kidney
disease; (iv) graft rejection; (v) end-stage renal diseases; and (vi)
hematological malignancies.
For the quantitative analysis of TLT formation frequency, kidneys
from 69 aged patients with RCC who underwent nephrectomy at
Kyoto University Hospital and from 16 patients with chronic py-
elonephritis who underwent nephrectomy at University Clinic of
Rhenish-Westphalian Technical University of Aachen were analyzed.
Clinical data including medical history, complications, and labora-
tory data are presented in Tables 1 and 2. CKD were defined as either
eGFR < 60 ml/min per 1.73 m2 or positive urinary protein. We
defined proteinuria positive as more than 1þ in urine dipstick test.
Among 69 aged patients with RCC, 29 patients had CKD including
nephrosclerosis and diabetic kidney disease. In total, 10 aged patients
exhibited proteinuria and 59 aged patients did not; 44 patients
exhibited eGFR > 60 ml/min per 1.73 m2 and 25 patients exhibited
eGFR < 60 ml/min per 1.73 m2. Although all the samples of ne-
phrectomies were diagnosed by nephropathologists as pyelonephri-
tis, and despite the indication of nephrectomies in our centers, the
possibility of uncertainty as to the clinical diagnoses cannot be
excluded.
Table 2 | Clinical characteristics of aged Japanese patients
evaluated in the study
Total CKDL CKDD TLTL TLTD
Aged patients (n) 69 40 29 36 33
Age (yr)
Average 70.8 69.7 72.2 70.1 71.5
Median 70.0 69.0 72.0 68.0 71.0
Range 60.0–89.0 60.0–85.0 62.0–89.0 60.0–85.0 60.0–89.0
Sex (n)
Male 34 20 14 19 15




Average 0.81 0.71 0.95a 0.78 0.84
Median 0.75 0.68 0.93 0.72 0.80
Range 0.40–1.53 0.40–0.95 0.50–1.53 0.50–1.53 0.40–1.41
eGFR (ml/min
per 1.73 m2)
Average 66.1 73.9 55.4a 67.9 64.1
Median 64.1 70.2 53.5 64.7 62.6
Range 29.3–116.5 60.2–114.0 29.3–116.5 35.7–99.0 29.3–116.5
Complication
DM (þ, %) 20.0 15.0 27.6b 19.4 21.2
HTN (þ, %) 62.3 55.0 72.4b 58.3 66.6
CKD, chronic kidney disease; Cr, creatinine; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; HTN, hypertension; TLT, tertiary lymphoid tissues.
CKD was defined either as eGFR < 60 ml/min or positive urinary protein, which was
defined as more than 1þ in urine dipstick test. Patients with HTN were defined as
those with a blood pressure of 140/90 mm Hg or above. eGFR was calculated using
the following formula: eGFR (ml/min per 1.73 m2) ¼ 194  Cr  1.094  Age  0.287
(in case of female,  0.739).
aP < 0.001 vs. aged patients without CKD. P values in comparison of serum Cr and
eGFR were calculated using a 2-tailed Student’s t test, while P values in comparison
of proportion of DM and HTN complication were calculated using Pearson’s chi-
squared test.
bNot significant.
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Identification and quantification of TLT
In the present study, we defined TLTs as the organized lymphocyte
aggregates with signs of proliferation. Identification of TLTwas based
on the unique localization of inflammatory cell aggregates and the
presence of B-cell aggregates. Quantification of TLT number and
stage in renal cortex was examined with immunofluorescence of (i)
CD3ε and CD20 and (ii) Ki67 and CD21 in 2 serial sections for each
individual and mouse and was assessed by an experienced renal
pathologist. TLT stage determination was performed based on the
presence of CD21-positive FDCs and germinal centers, in other
words, dense Ki67-positive B-cell clusters, within TLTs. TLTs con-
taining neither FDCs nor germinal centers were defined as stage I
Figure 8 | The developmental stage of tertiary lymphoid tissues (TLTs) in aged and pyelonephritic (Pyelo) human kidneys. (a–d)
Quantification of TLTs in aged and Pyelo human kidneys. (a) Relative frequencies of TLT development in kidneys of aged patients (n ¼ 69) and
patients with pyelonephritis (n ¼ 16). (b–e) Quantification of TLTs in aged patients and patients with pyelonephritis with renal TLTs (n ¼ 33
and 16, respectively). (b) Numbers of total TLTs; (c) stage I, II, and III TLTs; and (d) advanced-stage TLTs. (e) The proportion of stage I, II, and III
TLTs. (f) Relative frequencies of TLT development in aged human kidneys with or without chronic kidney disease (CKD) (n ¼ 29 and 40,
respectively). (g–j) Quantification of TLTs in aged patients with or without CKD, who exhibited renal TLTs (n ¼ 16 and 17, respectively). (g)
Numbers of total TLTs; (h) stage I, II, and III TLTs; and (i) advanced-stage TLTs. (j) Proportions of stage I, II, and III TLTs. (b–d,g–i) Values are
means  SD. Numbers of TLTs are the numbers per unit area of cortex (per mm2). The difference was analyzed using (b,d,g,i) 2-tailed Student’s
t test, (e,j) a generalized estimating equation, and (f) Pearson’s chi-squared test. *P < 0.01. NS, not significant.
Figure 9 | Heterogeneity of tertiary lymphoid tissues (TLTs) in human kidneys. In human kidneys, TLTs appeared to develop largely
through 3 distinct stages, which may represent the developmental stages. To evaluate the heterogeneity, we defined TLT stages by the
presence of follicular dendritic cells (FDCs) and germinal centers, which correspond to the presumed developmental stages. a-SMA, a-smooth
muscle actin; CXCL13, CXC chemokine ligand 13; HEV, high endothelial venule; p75NTR, p75 neurotrophin receptor; RA, retinoic acid; RALDH,
retinaldehyde dehydrogenases 2.
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TLTs, whereas TLTs that contain FDCs but lack germinal centers
were defined as stage II TLTs. TLTs with prominent FDCs and
germinal centers were defined as stage III. Advanced-stage TLTs were
defined as TLT with FDCs (i.e., stage II and III TLTs). The numbers
of TLTs were shown as the numbers per unit area of cortex (per
mm2) in mice and humans.
Animals
We utilized 12- to 13-month-old and 23-month-old C57BL6J male
mice and 10-month-old C57BL6J female mice. We purchased the
mice from Japan SLC (Nishi-ku Hamamatsu, Japan). Serum creatinine
was measured by the creatininase–N-(3-sulfopropyl)-3-methoxy-5-
methylaniline method. All mice were maintained under specific
pathogen-free conditions in the animal facility at Kyoto University.
All animal experiments were approved by the Animal Research Com-
mittee, Graduate School of Medicine, Kyoto University, and were
conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (U.S. National Institutes ofHealth, Bethesda,MD).
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Figure S1. Histologic findings in human pyelonephritic kidneys.
Histologic analysis of human pyelonephritic kidneys. Periodic acid–
Schiff (PAS) staining showed patchy tubulointerstitial scarring in (A)
geographic pattern, (B) intratubular aggregates of neutrophils, and
(C) multiple PAS-positive casts. Bars ¼ (A) 300 mm, (B) 50 mm, and (C)
200 mm.
Figure S2. Human pyelonephritic kidneys exhibited multiple
mononuclear cell aggregates. Histologic analysis of human
pyelonephritic kidneys. Periodic acid–Schiff (PAS) staining showed
(A) a chain of aggregates in the subcapsular area and cortico-
medullary area and (B) an aggregate within the renal capsule, (C) the
hilus area, and (D) submucosal area in the urinary tract. Yellow boxes
indicate the localization of inflammatory cell aggregates. Bars ¼ (A)
300 mm and (B–D) 200 mm.
Figure S3. a-Smooth muscle actin (a-SMA)-positive blood vessels and
podoplanin-positive lymphatic vessels are detectable around tertiary
lymphoid tissues in the pyelonephritic kidneys. Histologic analysis of
human pyelonephritic kidneys. (A,C) Periodic acid–Schiff (PAS)
staining showed inflammatory cell aggregates. (B,D) Immunofluo-
rescence of podoplanin (lymphatic vessel marker) and a-SMA showed
that a-SMA-positive arteries and lymphatic vessels were detectable
around inflammatory cell aggregates. Parts (A,B) and (C,D) are serial
sections. The white dotted line in (B,D) indicates inflammatory cell
aggregates. Bars ¼ 50 mm.
Figure S4. Tertiary lymphoid tissues (TLTs) in aged human kidneys
were detected in subcapsular, perivascular, and periglomerular areas.
Histologic analysis of aged human kidneys. Periodic acid–Schiff (PAS)
staining of (A) subcapsular, (B) perivascular, and (C) periglomerular
areas. (D–F) Immunofluorescence of CD3ε (a T-cell marker) and CD20
(B-cell marker). The white dotted line in parts (D), (E), and (F) indicate
localization of the renal capsule, artery, and glomerulus, respectively.
Bars ¼ (A–C) 200 mm and (D–F) 50 mm.
Figure S5. Larger aggregates were detected in more highly injured
areas in pyelonephritic kidneys. Histologic analysis of human
pyelonephritic kidneys. Periodic acid–Schiff (PAS) staining of the renal
cortex with (A) mildly, (B) moderately, and (C) highly injured areas. (D)
Masson trichrome (MTC) staining of the renal medulla with a highly
injured area. The yellow boxes in parts (B,C) show the localization of
TLT. Bars ¼ (A–D) 200 mm.
Figure S6. Foxp3-positive cells were detected within TLTs in human
kidneys. Immunohistochemical analysis of human pyelonephritic
kidneys. Immunohistochemical analysis of Foxp3 in human TLTs
showed the presence of Foxp3-positive cells within TLTs. The yellow
box in part (A) is magnified in part (B). Bars ¼ 20 mm.
Figure S7. Germinal center was composed of 2 subdomains, a light
zone and a dark zone. Immunohistochemical analysis of germinal
centers in human pyelonephritic kidneys. (A) Immunohistochemical
analysis of CD21 and (B) immunofluorescence of CD21 and Ki67 in
human TLTs showed that germinal centers in TLTs were composed of
2 compartments. One is characterized by CD21–strongly positive
follicular dendritic cells (FDCs) with scattered cell proliferation, and
the other is characterized by CD21–weakly positive FDCs with
proliferating cell cluster, which seem to correspond to light zone and
dark zone in secondary lymphoid organs, respectively. Bars ¼ 50 mm.
Figure S8. Foxp3þ regulatory T cells were detectable within mouse
TLTs and the numbers were decreased by Dex treatment. (A)
Immunofluorescence of CD3ε and Foxp3 in mouse TLTs 45 days after
IRI with or without treatment of Dex (Figure 6a). (B) CD4 and Foxp3
mRNA levels in the IRI kidneys (35: aged kidneys 35 days after 45-
minute IRI; 45: aged kidneys 45 days after 45-minute IRI; 45 Dex: aged
kidneys 45 days after 45-minute IRI treated with Dex from day 35 to
45). Bars ¼ (A, left) 50 mm and (A, right) 10 mm. Arrowheads indicate
CD3ε and Foxp3–double positive cells. In part (B), values are means 
SD. Statistical significance was assessed using 1-way ANOVA with
Bonferroni. *P < 0.01.
Figure S9. The number and stage of renal TLTs were comparable
between aged patients with or without a reduced GFR and
proteinuria. Quantification of TLT numbers and TLT stages of aged
patients with or without a reduced GFR (eGFR < 60 ml/min per 1.73
m2) as well as those with or without proteinuria among aged patients
with renal TLTs. Number of (A,D) total TLTs and (B,E) advanced-stage
TLT per section and (C,F) relative frequencies of stage I, II, and III TLTs
in the kidneys of aged patients with or without a reduced GFR
(eGFR < 60 ml/min per 1.73 m2) (n ¼ 13 and n ¼ 20, respectively),
and aged patients with or without proteinuria (n ¼ 8 and n ¼ 25,
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respectively). (A,B,D,E) Values are means  SD. (C,F) The difference in
proportion of advance-stage CKD (stage II and III TLTs) was analyzed.
The numbers of TLTs were shown as the numbers per unit area of
cortex (per mm2). Statistical significance was assessed using (A,B,D,E)
a 2-tailed Student’s t test and (C,F) generalized estimating equations.
*P < 0.01. Proteinuria positive was defined as more than 1þ in urine
dipstick test.
Table S1. Markers related with TLTs in human kidneys.
Table S2. The quantitative difference in TLT numbers and
percentages of advanced TLTs in Figure 5.
Table S3. The quantitative difference in TLT numbers and
percentages of advanced TLTs in Figure 6.
Table S4. The quantitative difference in TLT numbers and
percentages of advanced TLTs in aged and pyelonephritic human
kidneys in Figure 8.
Table S5. Primer sequences used for real-time PCR.
REFERENCES
1. Sato Y, Yanagita M. Immunology of aging kidney. Nat Rev Nephrol.
2019;15:625–640.
2. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like
structures in infection, cancer and autoimmunity. Nat Rev Immunol.
2014;14:447–462.
3. Neyt K, Perros F, GeurtsvanKessel CH, Hammad H, Lambrecht BN. Tertiary
lymphoid organs in infection and autoimmunity. Trends Immunol.
2012;33:297–305.
4. Ansel KM, Ngo VN, Hyman PL, et al. A chemokine-driven positive
feedback loop organizes lymphoid follicles. Nature. 2000;406:309–314.
5. van de Pavert SA, Oliver BJ, Goverse G, et al. Chemokine CXCL13 is
essential for lymph node initiation and is induced by retinoic acid and
neuronal stimulation. Nat Immunol. 2009;10:1193–1199.
6. Nielen MM, van der Horst AR, van Schaardenburg D, et al. Antibodies to
citrullinated human fibrinogen (ACF) have diagnostic and prognostic
value in early arthritis. Ann Rheum Dis. 2005;64:1199–1204.
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-
cyclic citrullinated protein antibodies in rheumatoid arthritis: a
systematic literature review. Ann Rheum Dis. 2006;65:845–851.
8. Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures
support ongoing production of class-switched autoantibodies in
rheumatoid synovium. PLoS Med. 2009;6:e1.
9. Ge C, Tong D, Liang B, et al. Anti-citrullinated protein antibodies cause
arthritis by cross-reactivity to joint cartilage. JCI Insight. 2017;2:93688.
10. Sato Y, Mii A, Hamazaki Y, et al. Heterogeneous fibroblasts underlie age-
dependent tertiary lymphoid tissues in the kidney. JCI Insight. 2016;1:
e87680.
11. Sato Y, Yanagita M. Resident fibroblasts in the kidney: a major driver of
fibrosis and inflammation. Inflamm Regen. 2017;37:17.
12. Steinmetz OM, Velden J, Kneissler U, et al. Analysis and classification of B-
cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int.
2008;74:448–457.
13. Thaunat O, Field AC, Dai J, et al. Lymphoid neogenesis in chronic
rejection: evidence for a local humoral alloimmune response. Proc Natl
Acad Sci U S A. 2005;102:14723–14728.
14. Hsiao HM, Li W, Gelman AE, Krupnick AS, Kreisel D. The role of lymphoid
neogenesis in allografts. Am J Transplant. 2016;16:1079–1085.
15. Pei G, Zeng R, Han M, et al. Renal interstitial infiltration and tertiary
lymphoid organ neogenesis in IgA nephropathy. Clin J Am Soc Nephrol.
2014;9:255–264.
16. Segerer S, Schlondorff D. B cells and tertiary lymphoid organs in renal
inflammation. Kidney Int. 2008;73:533–537.
17. Srivastava A, Palsson R, Kaze AD, et al. The prognostic value of
histopathologic lesions in native kidney biopsy specimens: results from
the Boston Kidney Biopsy Cohort Study. J Am Soc Nephrol. 2018;29:2213–
2224.
18. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology:
chronic pyelonephritis. Am J Kidney Dis. 2016;68:e23–e25.
19. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology:
acute pyelonephritis. Am J Kidney Dis. 2016;68:e21–e22.
20. Heesters BA, Myers RC, Carroll MC. Follicular dendritic cells: dynamic
antigen libraries. Nat Rev Immunol. 2014;14:495–504.
21. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and
differentiation dynamics of human CD4þ T cells expressing the FoxP3
transcription factor. Immunity. 2009;30:899–911.
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development
by the transcription factor Foxp3. Science. 2003;299:1057–1061.
23. Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics.
Immunity. 2016;45:471–482.
24. Krautler NJ, Kana V, Kranich J, et al. Follicular dendritic cells emerge from
ubiquitous perivascular precursors. Cell. 2012;150:194–206.
25. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8þ tumor-infiltrating
lymphocytes and a high CD8þ/regulatory T cell ratio are associated with
favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:
18538–18543.
26. Thaunat O, Patey N, Caligiuri G, et al. Chronic rejection triggers the
development of an aggressive intragraft immune response through
recapitulation of lymphoid organogenesis. J Immunol. 2010;185:717–728.
27. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune
responses and tubulointerstitial inflammation in human lupus nephritis.
J Immunol. 2011;186:1849–1860.
28. Sato Y, Yanagita M. Functional heterogeneity of resident fibroblasts in
the kidney. Proc Jpn Acad Ser B Phys Biol Sci. 2019;95:468–478.
29. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD
progression. Am J Physiol Renal Physiol. 2018;315:F1501–F1512.
30. Lehmann-Horn K, Wang SZ, Sagan SA, et al. B cell repertoire
expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight.
2016;1:e87234.
31. Fletcher AL, Acton SE, Knoblich K. Lymph node fibroblastic reticular cells
in health and disease. Nat Rev Immunol. 2015;15:350–361.
32. Hu D, Mohanta SK, Yin C, et al. Artery tertiary lymphoid organs
control aorta immunity and protect against atherosclerosis via vascular
smooth muscle cell lymphotoxin beta receptors. Immunity. 2015;42:
1100–1115.
33. Delventhal S, Hensel A, Petzoldt K, Pabst R. Effects of microbial
stimulation on the number, size and activity of bronchus-associated
lymphoid tissue (BALT) structures in the pig. Int J Exp Pathol. 1992;73:
351–357.
34. Hwang JY, Randall TD, Silva-Sanchez A. Inducible bronchus-associated
lymphoid tissue: taming inflammation in the lung. Front Immunol.
2016;7:258.
35. Katakai T. Marginal reticular cells: a stromal subset directly descended
from the lymphoid tissue organizer. Front Immunol. 2012;3:200.
36. Furman D, Chang J, Lartigue L, et al. Expression of specific
inflammasome gene modules stratifies older individuals into two
extreme clinical and immunological states. Nat Med. 2017;23:174–184.
c l i n i ca l i nves t iga t i on Y Sato et al.: TLT stages reflect kidney inflammation
16 Kidney International (2020) -, -–-
